SCHEDULE: Deep Track Capital Divests Entire Stake in Palisade Bio

Deep Track Capital and its affiliated entities have reported a complete divestment of their beneficial ownership in Palisade Bio, Inc., holding 0% of the common stock.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., David Kroin, and Deep Track Special Opportunities Fund, LP have filed an Amendment No. 1 to their Schedule 13G.
• The filing indicates that as of December 31, 2025, these reporting persons beneficially own 0 shares of Palisade Bio, Inc. common stock.
• This represents 0% of the class of securities, based on 149,003,210 shares outstanding as of November 5, 2025, as reported in the issuer's 10-Q filed on November 10, 2025.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the complete divestment by a specialized institutional investor typically signals a loss of confidence in the company's prospects, which could pressure the stock price.

Negatives

• Deep Track Capital and its affiliated funds, which previously held a stake, have completely divested their holdings in Palisade Bio, Inc.
• The reduction to 0% ownership by these institutional entities may signal a loss of institutional confidence in the company's future prospects.

Risks

• Loss of institutional investor support could negatively impact investor sentiment and the company's share price.
• Reduced liquidity in the stock may occur if other institutional investors follow suit or if this divestment is perceived as a negative signal.

Future Outlook

NA

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional investor divestments, particularly a complete exit by a specialized biotechnology fund like Deep Track Capital, can be a significant indicator for the market. In the volatile biotechnology sector, such moves often reflect a re-evaluation of a company's pipeline, clinical trial prospects, or overall strategic direction, potentially signaling a lack of confidence compared to peers.

Stakeholder Impact

• Shareholders may experience negative sentiment and potential downward pressure on share price due to the institutional divestment.
• Management could face increased scrutiny regarding the company's strategy and performance that led to the investor's exit.

Key Dates

Recommendation

The complete divestment by a significant institutional investor like Deep Track Capital suggests a fundamental re-evaluation of Palisade Bio's investment thesis. This action typically signals a lack of confidence in the company's future prospects, making it prudent for investors to consider selling their holdings to mitigate potential downside risk.

Keywords

Palisade Bio, Deep Track Capital, Schedule 13G, Ownership Disclosure, Institutional Investor, Biotechnology, Divestment, Common Stock